The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
Open accessAbstract
Background: Immune-inflammatory biomarkers (IIBs) showed a prognostic relevance in patients with metastatic CRC (mCRC). We aimed at evaluating the prognostic power of a new comprehensive biomarker, the Pan-Immune-Inflammation Value (PIV), in patients with mCRC receiving first-line therapy. Methods: In the present pooled-analysis, we included patients enrolled in the Valentino and TRIBE trials. PIV was calculated as: (neutrophil count × platelet count × monocyte count)/lymphocyte count. A cut-off was determined using the maximally selected rank statistics method. Generalised boosted regression (GBR), the Kaplan–Meier method and Cox hazards regression models were used for survival analyses. Results: A total of 438 patients were included. Overall, 208 patients (47%) had a low-baseline PIV and 230 (53%) had a high-baseline PIV. Patients with high PIV experienced a worse PFS (HR, 1.66; 95% CI, 1.36–2.03, P < 0.001) and worse OS (HR, 2.01; 95% CI, 1.57–2.57; P < 0.001) compared to patients with low PIV. PIV outperformed the other IIBs in the GBR model and in the multivariable models. Conclusion: PIV is a strong predictor of survival outcomes with better performance than other well-known IIBs in patients with mCRC treated with first-line therapy. PIV should be prospectively validated to better stratify mCRC patients undergoing first-line therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greedy function approximation: A gradient boosting machine
Friedman, J. H. (2001) · The Annals of Statistics · doi:10.1214/aos/1013203451 · Cited by 30,731
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Friedman, J. H. (2002) · Computational Statistics & Data Analysis · doi:10.1016/s0167-9473(01)00065-2 · Cited by 7,067
Hu, B., Yang, X.-R., Xu, Y., Sun, Y.-F., Sun, C., Guo, W., Zhang, X., Wang, W.-M., Qiu, S.-J., Zhou, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0442 · Cited by 2,493
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092
Self-citationTumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Maximally Selected Rank Statistics
Lausen, B., & Schumacher, M. (1992) · Biometrics · doi:10.2307/2532740 · Cited by 643
Dolan, R. D., McSorley, S. T., Horgan, P. G., Laird, B., & McMillan, D. C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.06.002 · Cited by 351
Metadata
- Authors
- Fucà, G., Guarini, V., Antoniotti, C., Morano, F., Moretto, R., Corallo, S., Marmorino, F., Lonardi, S., Rimassa, L., Sartore-Bianchi, A., Borelli, B., Tampellini, M., Bustreo, S., Claravezza, M., Boccaccino, A., Murialdo, R., Zaniboni, A., Tomasello, G., Loupakis, F., Adamo, V., Tonini, G., Cortesi, E., de Braud, F., Cremolini, C., & Pietrantonio, F.
- Venue
- British Journal of Cancer
- Published
- 2020-05-19
- Volume
- 123
- Issue
- 3
- Pages
- 403-409
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W3024839384
- Cited by
- 398
- References
- 22
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. https://app.cochat.ai/papers/10.1038/s41416-020-0894-7
- The paper
- Fucà, G., Guarini, V., Antoniotti, C., Morano, F., Moretto, R., Corallo, S., Marmorino, F., Lonardi, S., Rimassa, L., Sartore-Bianchi, A., Borelli, B., Tampellini, M., Bustreo, S., Claravezza, M., Boccaccino, A., Murialdo, R., Zaniboni, A., Tomasello, G., Loupakis, F., . . . Pietrantonio, F. (2020). The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. British Journal of Cancer. https://doi.org/10.1038/s41416-020-0894-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
